Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

SCOTTSDALE, Ariz. — June 16, 2025 — The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those ...

The National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its ...

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the ...

Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

Carmen Iris Albaladejo told Newsweek that her husband "feels the weight of his life being taken from him piece by piece" following his diagnosis.

Among 47 patients with any of several forms of idiopathic inflammatory myositis (IIM) who took efgartigimod (Vyvgart Hytrulo) ...